Clinical Trial

Androgenic Alopecia TH07 Clinical Trial

Study acronym: MATT
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-24.
Trial Details
NCT Number NCT07435012
Lead Sponsor Triple Hair Inc
Conditions Androgenic Alopecia
Enrollment 420 participants
Start Date 2026-04
Primary Completion 2027-12 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-16